These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 532391)

  • 1. [DNFB reaction in bladder cancer, an immunological study].
    Hudemann B; Günther M; Seyfarth M
    Z Urol Nephrol; 1979 Oct; 72(10):729-32. PubMed ID: 532391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of DNFB skin testing in patients with bladder cancer (author's transl)].
    Hudemann B; Seyfarth M
    Arch Geschwulstforsch; 1980; 50(2):173-7. PubMed ID: 7436702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local BCG-immunotherapy in bladder cancer patients. Immunological follow-up studies.
    Seyfarth M; Hudemann B; Nizze H; Riedel H; Werner H
    Arch Geschwulstforsch; 1982; 52(1):63-6. PubMed ID: 7082133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The prognostic significance of the immune status (DNCB-test) in patients with carcinoma of the bladder, checked by observation of the course of disease (author's transl)].
    Flamm J; Burkert S
    Wien Med Wochenschr; 1981; 131(13-14):339-43. PubMed ID: 7281701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
    Flamm J; Grof F
    Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological responsiveness in patients with bladder cancer.
    Fahey JL; Brosman S; Dorey F
    Cancer Res; 1977 Aug; 37(8 Pt 2):2875-8. PubMed ID: 872117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A contribution to the early diagnosis and differential diagnosis of bladder neoplasms by means of immunological methods].
    Günther M; Friedrich A; Nizze H; Seyfarth M; Jenssen HL; Köhler H; Werner H; Hudemann B; Riedel R; Erdmann T
    Z Urol Nephrol; 1978 Feb; 71(2):81-7. PubMed ID: 77116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cellular immune reactions in patients with malignant tumors: correlation of phytohemagglutinin-induced lymphocyte transformation and epicutanous tests using dinitrofluorobenzene].
    Schwarze G; Pappas A
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1852-4. PubMed ID: 1030123
    [No Abstract]   [Full Text] [Related]  

  • 10. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients.
    Li CC; Chang TH; Wu WJ; Ke HL; Huang SP; Tsai PC; Chang SJ; Shen JT; Chou YH; Huang CH
    Eur Urol; 2008 Nov; 54(5):1127-34. PubMed ID: 18243511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of 1-fluoro-2,4-dinitrobenzene as an affinity label for the antigen receptor of delayed hypersensitivity.
    Godfrey HP
    Immunology; 1976 Oct; 31(4):665-73. PubMed ID: 789233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tissue type plasminogen activator antigen in urine of patients with bladder cancer].
    Iwan-Zietek I; Zietek Z; Kotschy M; Wolski Z; Wiśniewska E; Zekanowska E
    Pol Merkur Lekarski; 1997 Jun; 2(12):366-7. PubMed ID: 9424324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunologic behavior of carcinoma in situ of the bladder].
    Hudemann B; Riedel H; Seyfarth M; Werner H; Erdmann T
    Z Urol Nephrol; 1982 Apr; 75(4):253-7. PubMed ID: 7102136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of the DNCB test in bladder cancer. Pretreatment evaluation of immune function and 5-year follow-up of patients with urinary bladder cancer.
    Flamm J; Sagaster P; Micksche M
    Urol Int; 1984; 39(5):257-63. PubMed ID: 6506358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dedifferentiated superficial bladder cancer with invasion of the lamina propria (pT1 GIII)].
    Flamm J
    Z Urol Nephrol; 1986 Sep; 79(9):511-6. PubMed ID: 3788301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
    Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
    Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo skin test in carcinoma bladder.
    Gupta NP; Rajagopal V; Malaviya AN; Singh SM
    Indian J Cancer; 1984 Nov-1985 Jan; 21(5-6):163-5. PubMed ID: 6545227
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current immunologic findings in bladder cancer].
    Seyfarth M; Hudemann B; Erdmann T
    Z Urol Nephrol; 1982 Mar; 75(3):153-7. PubMed ID: 7102126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of the stromal reaction in bladder cancer].
    Goertchen R; Kluge R; Stosiek P
    Arch Geschwulstforsch; 1988; 58(5):327-32. PubMed ID: 3202683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.